TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces today that cash and cash equivalents totaled €8.3 million at December 31, 2019.
The activities of ABIONYX Pharma are focused on the discovery and development of innovative therapies to improve the lives of patients; the company did not generate any revenues during 2019, as expected.
As announced previously, possible collaborations with external partners are under consideration, and the company reasserts its commitment to communicating a new strategic development plan by the end of the first quarter of 2020.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.